Dishman Carbogen Amcis Ltd has largely indulged in developing sophisticated infrastructure, enabling the production of various novel dosage formulations in soft gelatin capsules, such as Therapeutic, Nutraceutical, and OTC. With 1 pilot Softgel facility (5000 ft² with 30 million capsules per annum capacity) and a commercial softgel facility (25000 ft² with 300 million capsules per annum capacity), we have established an in-house combined production capacity of 330 million softgel capsules every year.

The facility's total built-up area is approximately 30,000 ft², with a fully automated packing line for blisters.

Our end-to-end CRAMs capabilities related to pharmaceutical and dietary supplements include:

• Formulation Development
• Technology transfer
• Scale-up & commercial manufacturing
• Analytical services
• Regulatory assistance
• Robust quality management system
• Stability studies as per ICH guidelines
• Private labeling & secure packing
• Latest, state of the art two 8” Fully automated, 21 CFR complaint, Encapsulation technology with PLC control
• Sterile injectables

The plant is designed to meet the highest regulatory quality standards, including EU, USFDA, WHO GMP, and has a well-equipped warehouse for intermediates and finished goods with controlled temperature & humidity.

With a primary focus on the formulation of complex, potent, and challenging drug products from preclinical to clinical batches in both liquid or freeze-dried form, our facility in Riom has been part of the Dishman Carbogen Amcis Ltd Group since early 2012 and is inspected by the French Health Authority (ANSM) and has ISO 22716 Cosmetics GMP Standard Accreditation.